Most Recent
US biotech giant Gilead has struck back at a patent infringement lawsuit brought by a specialist HIV pharmaceutical company majority owned by GlaxoSmithKline, saying the patent at the centre of the lawsuit is invalid.
The NSW Supreme Court has approved a settlement in Australia's first privacy class action, which was brought against the NSW government over a data breach by a contractor who sold private details of 130 ambulance workers to personal injury law firms, including Bannister Law.
Australian drug maker Juno Pharmaceuticals has hit back at claims it is infringing the patent for US-based Pfizer's post-operative pain killer Dynastat, saying the patent is invalid.
Pfizer, maker of the blockbuster rheumatoid arthritis biologic Enbrel, has taken generic drug maker Sandoz to court for information on its Enbrel biosimilar, after winning a bid for preliminary discovery against Samsung Biopis to pursue a possible infringement case over the same drug.
A class action against the NSW government over a contractor who took private details of 130 ambulance workers to on-sell to personal injury law firms, including Bannister Law, has settled.
Mobility equipment provider Country Care Group will fight for the dismissal of three charges brought by federal prosecutors in the country's first criminal cartel case against an Australian business.
A Federal Court judge has reversed a prior ruling expanding the class in a lawsuit against Johnson & Johnson unit Ethicon over allegedly defective pelvic mesh implants, saying he had "no confidence" new group members would have sufficient opportunity to opt out before judgment is delivered in a few weeks.
An impending judgment in the long-running class action against Johnson & Johnson unit Ethicon over allegedly defective pelvic mesh implants has sent the parties scrambling about opt out notices and the Federal Court considering reversing prior orders that expanded the group definition.
Cosmetic Institute director Dr Eddy Dona has flagged that he may drag insurers of his now collapsed medical chain into a class action brought against him and the company over allegedly botched breast implants.
UK biopharmaceutical company Kymab may attack experiments done by US biotechnology giant Regeneron creating genetically modified mice with splices of human genomes, as it defends its proposed patent for a human rat.